CCNE2
CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Overview
Essential for the control of the cell cycle at the late G1 and early S phase.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Palbociclib and CDK Inhibitor SNS-032.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 1 · What it is
CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
- 2 · What goes wrong in cancer
Essential for the control of the cell cycle at the late G1 and early S phase. Location: Nucleus (UniProt).
- 3 · How drugs use it
No product in this corpus aims at CCNE2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:1590 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O96020 (protein name, function text, keywords and locations (REST API)); CIViC gene CCNE2 (2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer (GraphQL API, CC0))
Biology
Essential for the control of the cell cycle at the late G1 and early S phase. Location: Nucleus (UniProt). Locus 8q22.1 (HGNC).
- Breast cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CCNE2" OR ABSTRACT:"CCNE2" OR TITLE:"cyclin E2" OR ABSTRACT:"cyclin E2" OR TITLE:"G1/S-specific cyclin-E2" OR ABSTRACT:"G1/S-specific cyclin-E2" OR TITLE:"CYCE2" OR ABSTRACT:"CYCE2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCNE2, not a curated reading list.